OBJECTIVE: Complement-mediated vasculopathy of muscle and skin are clinical features of juvenile dermatomyositis (JDM). We assess gene copy-number variations (CNVs) for complement C4 and its isotypes, C4A and C4B, in genetic risks and pathogenesis of JDM. METHODS: The study population included 105 patients with JDM and 500 healthy European Americans. Gene copy-numbers (GCNs) for total C4, C4A, C4B and HLA-DRB1 genotypes were determined by Southern blots and qPCRs. Processed activation product C4d bound to erythrocytes (E-C4d) was measured by flow cytometry. Global gene-expression microarrays were performed in 19 patients with JDM and seven controls using PAXgene-blood RNA. Differential expression levels for selected genes were validated by qPCR. RESULTS: Significantly lower GCNs and differences in distribution of GCN groups for total C4 and C4A were observed in JDM versus controls. Lower GCN of C4A in JDM remained among HLA DR3-positive subjects (p=0.015). Homozygous or heterozygous C4A-deficiency was present in 40.0% of patients with JDM compared with 18.2% of controls (OR=3.00 (1.87 to 4.79), p=8.2×10(-6)). Patients with JDM had higher levels of E-C4d than controls (p=0.004). In JDM, C4A-deficient subjects had higher levels of E-C4d (p=0.0003) and higher frequency of elevated levels of multiple serum muscle enzymes at diagnosis (p=0.0025). Microarray profiling of blood RNA revealed upregulation of type I interferon-stimulated genes and lower abundance of transcripts for T-cell and chemokine function genes in JDM, but this was less prominent among C4A-deficient or DR3-positive patients. CONCLUSIONS: Complement C4A deficiency appears to be an important factor for the genetic risk and pathogenesis of JDM, particularly in patients with a DR3-positive background. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVE: Complement-mediated vasculopathy of muscle and skin are clinical features of juvenile dermatomyositis (JDM). We assess gene copy-number variations (CNVs) for complement C4 and its isotypes, C4A and C4B, in genetic risks and pathogenesis of JDM. METHODS: The study population included 105 patients with JDM and 500 healthy European Americans. Gene copy-numbers (GCNs) for total C4, C4A, C4B and HLA-DRB1 genotypes were determined by Southern blots and qPCRs. Processed activation product C4d bound to erythrocytes (E-C4d) was measured by flow cytometry. Global gene-expression microarrays were performed in 19 patients with JDM and seven controls using PAXgene-blood RNA. Differential expression levels for selected genes were validated by qPCR. RESULTS: Significantly lower GCNs and differences in distribution of GCN groups for total C4 and C4A were observed in JDM versus controls. Lower GCN of C4A in JDM remained among HLA DR3-positive subjects (p=0.015). Homozygous or heterozygous C4A-deficiency was present in 40.0% of patients with JDM compared with 18.2% of controls (OR=3.00 (1.87 to 4.79), p=8.2×10(-6)). Patients with JDM had higher levels of E-C4d than controls (p=0.004). In JDM, C4A-deficient subjects had higher levels of E-C4d (p=0.0003) and higher frequency of elevated levels of multiple serum muscle enzymes at diagnosis (p=0.0025). Microarray profiling of blood RNA revealed upregulation of type I interferon-stimulated genes and lower abundance of transcripts for T-cell and chemokine function genes in JDM, but this was less prominent among C4A-deficient or DR3-positive patients. CONCLUSIONS:Complement C4A deficiency appears to be an important factor for the genetic risk and pathogenesis of JDM, particularly in patients with a DR3-positive background. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: S A Robb; A H Fielder; C E Saunders; N J Davey; M W Burley; D H Lord; J R Batchelor; V Dubowitz Journal: Hum Immunol Date: 1988-05 Impact factor: 2.850
Authors: Warren R Davis; James E Halls; Amaka C Offiah; Clarissa Pilkington; Catherine M Owens; Karen Rosendahl Journal: Rheumatology (Oxford) Date: 2011-10-04 Impact factor: 7.580
Authors: Yee Ling Wu; Stephanie L Savelli; Yan Yang; Bi Zhou; Brad H Rovin; Daniel J Birmingham; Haikady N Nagaraja; Lee A Hebert; C Yung Yu Journal: J Immunol Date: 2007-09-01 Impact factor: 5.422
Authors: E Nissilä; K Korpela; A I Lokki; R Paakkanen; S Jokiranta; W M de Vos; M-L Lokki; K-L Kolho; S Meri Journal: Clin Exp Immunol Date: 2017-09-25 Impact factor: 4.330
Authors: Katherine E Lintner; Yee Ling Wu; Yan Yang; Charles H Spencer; Georges Hauptmann; Lee A Hebert; John P Atkinson; C Yung Yu Journal: Front Immunol Date: 2016-02-15 Impact factor: 7.561
Authors: Simon Rothwell; Hector Chinoy; Janine A Lamb; Frederick W Miller; Lisa G Rider; Lucy R Wedderburn; Neil J McHugh; Andrew L Mammen; Zoe E Betteridge; Sarah L Tansley; John Bowes; Jiří Vencovský; Claire T Deakin; Katalin Dankó; Limaye Vidya; Albert Selva-O'Callaghan; Lauren M Pachman; Ann M Reed; Øyvind Molberg; Olivier Benveniste; Pernille R Mathiesen; Timothy R D J Radstake; Andrea Doria; Jan de Bleecker; Annette T Lee; Michael G Hanna; Pedro M Machado; William E Ollier; Peter K Gregersen; Leonid Padyukov; Terrance P O'Hanlon; Robert G Cooper; Ingrid E Lundberg Journal: Ann Rheum Dis Date: 2019-05-28 Impact factor: 19.103